Bausch + LombBLCO
About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Employees: 13,500
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
300% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 4 (+3) [Q2]
101% more call options, than puts
Call options by funds: $7.11M | Put options by funds: $3.53M
0.01% more ownership
Funds ownership: 10.46% [Q1] → 10.47% (+0.01%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 26
10% less capital invested
Capital invested by funds: $535M [Q1] → $483M (-$52.2M) [Q2]
14% less funds holding
Funds holding: 106 [Q1] → 91 (-15) [Q2]
41% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 32
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Morgan Stanley Patrick Wood | 10%downside $13 | Equal-Weight Maintained | 1 Aug 2025 |
HC Wainwright & Co. Yi Chen | 10%upside $16 | Buy Maintained | 31 Jul 2025 |
Wells Fargo Larry Biegelsen | 3%upside $15 | Equal-Weight Maintained | 31 Jul 2025 |
Citigroup Joanne Wuensch | 3%upside $15 | Neutral Maintained | 9 Jul 2025 |
Evercore ISI Group Vijay Kumar | 10%upside $16 | Outperform Maintained | 8 Jul 2025 |
Financial journalist opinion
Based on 8 articles about BLCO published over the past 30 days
